Peggy van der Pol
Research Subjects
Research Interests
Peggy van der Pol has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Dirk J. Korf
11 shared publications- Nienke Liebregts
Bonger Institute of Criminology, Law Faculty University of Amsterdam Amsterdam The Netherlands
10 shared publications Ron de Graaf
9 shared publicationsWim van Den Brink
9 shared publicationsMargriet van Laar
8 shared publicationsMargriet Van Laar
Utrecht,Nederland
3 shared publications
Latest Publications
- Open Access
- 26 November 2021
- Published by S. Karger AG in European Addiction Research
- Vol. 28 (2) , 155-160
Drug Use Changes at the Individual Level: Results from a Longitudinal, Multisite Survey in Young Europeans Frequenting the Nightlife Scene
Background: Monitoring emerging trends in the increasingly dynamic European drug market is vital; however, information on change at the individual level is scarce. In the current study, we investigated changes in drug use over 12 months in European nightlife attendees. Method: In this longitudinal online survey, changes in substances used, use frequency in continued users, and relative initiation of use at follow-up were assessed for 20 different substances. To take part, participants had to be aged 18–34 years; be from Belgium, Italy, the Netherlands, Sweden, or the UK; and have attended at least 6 electronic music events in the past 12 months at baseline. Of 8,045 volunteers at baseline, 2,897 completed the survey at both time points (36% follow-up rate), in 2017 and 2018. Results: The number of people using ketamine increased by 21% (p < 0.001), and logarithmized frequency of use in those continuing use increased by 15% (p < 0.001; 95% CI: 0.07–0.23). 4-Fluoroamphetamine use decreased by 27% (p < 0.001), and logarithmized frequency of use in continuing users decreased by 15% (p < 0.001, 95% CI: −0.48 to −0.23). The drugs with the greatest proportion of relative initiation at follow-up were synthetic cannabinoids (73%, N = 30), mephedrone (44%, N = 18), alkyl nitrites (42%, N = 147), synthetic dissociatives (41%, N = 15), and prescription opioids (40%, N = 48). Conclusions: In this European nightlife sample, ketamine was found to have the biggest increase in the past 12 months, which occurred alongside an increase in frequency of use in continuing users. The patterns of uptake and discontinuation of alkyl nitrates, novel psychoactive substances, and prescription opioids provide new information that has not been captured by existing cross-sectional surveys. These findings demonstrate the importance of longitudinal assessments of drug use and highlight the dynamic nature of the European drug landscape.
- 26 November 2021
- Published by S. Karger AG in European Addiction Research
- Vol. 28 (2) , 155-160
Open AccessDrug Use Changes at the Individual Level: Results from a Longitudinal, Multisite Survey in Young Europeans Frequenting the Nightlife Scene
Background: Monitoring emerging trends in the increasingly dynamic European drug market is vital; however, information on change at the individual level is scarce. In the current study, we investigated changes in drug use over 12 months in European nightlife attendees. Method: In this longitudinal online survey, changes in substances used, use frequency in continued users, and relative initiation of use at follow-up were assessed for 20 different substances. To take part, participants had to be aged 18–34 years; be from Belgium, Italy, the Netherlands, Sweden, or the UK; and have attended at least 6 electronic music events in the past 12 months at baseline. Of 8,045 volunteers at baseline, 2,897 completed the survey at both time points (36% follow-up rate), in 2017 and 2018. Results: The number of people using ketamine increased by 21% (p < 0.001), and logarithmized frequency of use in those continuing use increased by 15% (p < 0.001; 95% CI: 0.07–0.23). 4-Fluoroamphetamine use decreased by 27% (p < 0.001), and logarithmized frequency of use in continuing users decreased by 15% (p < 0.001, 95% CI: −0.48 to −0.23). The drugs with the greatest proportion of relative initiation at follow-up were synthetic cannabinoids (73%, N = 30), mephedrone (44%, N = 18), alkyl nitrites (42%, N = 147), synthetic dissociatives (41%, N = 15), and prescription opioids (40%, N = 48). Conclusions: In this European nightlife sample, ketamine was found to have the biggest increase in the past 12 months, which occurred alongside an increase in frequency of use in continuing users. The patterns of uptake and discontinuation of alkyl nitrates, novel psychoactive substances, and prescription opioids provide new information that has not been captured by existing cross-sectional surveys. These findings demonstrate the importance of longitudinal assessments of drug use and highlight the dynamic nature of the European drug landscape.
- 4 April 2017
- Published by Springer Nature in Verslaving
- Vol. 13 (2) , 102-119
Wat doen XTC-gebruikers om risico’s te beperken?
- 4 April 2017
- Published by Springer Nature in Verslaving
- Vol. 13 (2) , 102-119
Wat doen XTC-gebruikers om risico’s te beperken?
- 25 February 2016
- Published by Elsevier in International Journal of Drug Policy
- Vol. 34, 58-64
Limitations to the Dutch cannabis toleration policy
- 25 February 2016
- Published by Elsevier in International Journal of Drug Policy
- Vol. 34, 58-64
Limitations to the Dutch cannabis toleration policy
- 12 June 2015
- Published by Springer Nature in Verslaving
- Vol. 11 (2) , 103-115
Wel of geen hulp zoeken voor cannabisafhankelijkheid?
- 12 June 2015
- Published by Springer Nature in Verslaving
- Vol. 11 (2) , 103-115
Wel of geen hulp zoeken voor cannabisafhankelijkheid?
- 13 April 2015
- Published by American Psychological Association (APA)
Marijuana Motives Measure--Dutch Extended Version
- 13 April 2015
- Published by American Psychological Association (APA)
Marijuana Motives Measure--Dutch Extended Version
Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study
Background and Aims: Increased delta‐9‐tetrahydrocannabinol (THC) concentrations in cannabis may lead to higherTHCexposure, cannabis dependence and treatment need, but users may also adapt the actual intake ofTHCthrough reduced inhalation ofTHCcontaining smoke (titration). We investigated whether consumers of stronger cannabis use less cannabis per joint or inhale less smoke than those using less potent cannabis and whether these factors predict cannabis dependence severity.Methods: Heavy cannabis users (n = 98) brought their own cannabis, rolled a joint and smoked itad libitumin a naturalistic setting. We analysed the content of the joint, its association with smoking behaviour and the cross‐sectional and prospective (1.5‐year follow‐up) relations between smoking behaviour and cannabis dependence severity (total number ofDSM‐IVdependence symptoms).Results: THCconcentration in cannabis (range 1.10–24.70%) was correlated positively with cannabis dose per joint (b = 0.008,P = 0.01), but the resultingTHCconcentration per joint (range 0.24–15.72%) was associated negatively with inhalation volume (b = −0.05,P = 0.03). Smoking behaviour measures (number of puffs, inhaled volume, reduction of puff volume and puff duration while smoking) predicted follow‐up dependence severity, independently of baseline dependence severity and monthlyTHCdose (number of joints × cannabis dose × cannabisTHCconcentration). MonthlyTHCdose only predicted follow‐up dependence severity when unadjusted for baseline severity.Conclusions: Cannabis users titrate their delta‐9‐tetrahydrocannabinol intake by inhaling lower volumes of smoke when smoking strong joints, but this does not fully compensate for the higher cannabis doses per joint when using strong cannabis. Thus, users of more potent cannabis are generally exposed to more delta‐9‐tetrahydrocannabinol. Smoking behaviour appears to be a stronger predictor for cannabis dependence severity than monthly delta‐9‐tetrahydrocannabinol dose.
Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study
Background and Aims: Increased delta‐9‐tetrahydrocannabinol (THC) concentrations in cannabis may lead to higherTHCexposure, cannabis dependence and treatment need, but users may also adapt the actual intake ofTHCthrough reduced inhalation ofTHCcontaining smoke (titration). We investigated whether consumers of stronger cannabis use less cannabis per joint or inhale less smoke than those using less potent cannabis and whether these factors predict cannabis dependence severity.Methods: Heavy cannabis users (n = 98) brought their own cannabis, rolled a joint and smoked itad libitumin a naturalistic setting. We analysed the content of the joint, its association with smoking behaviour and the cross‐sectional and prospective (1.5‐year follow‐up) relations between smoking behaviour and cannabis dependence severity (total number ofDSM‐IVdependence symptoms).Results: THCconcentration in cannabis (range 1.10–24.70%) was correlated positively with cannabis dose per joint (b = 0.008,P = 0.01), but the resultingTHCconcentration per joint (range 0.24–15.72%) was associated negatively with inhalation volume (b = −0.05,P = 0.03). Smoking behaviour measures (number of puffs, inhaled volume, reduction of puff volume and puff duration while smoking) predicted follow‐up dependence severity, independently of baseline dependence severity and monthlyTHCdose (number of joints × cannabis dose × cannabisTHCconcentration). MonthlyTHCdose only predicted follow‐up dependence severity when unadjusted for baseline severity.Conclusions: Cannabis users titrate their delta‐9‐tetrahydrocannabinol intake by inhaling lower volumes of smoke when smoking strong joints, but this does not fully compensate for the higher cannabis doses per joint when using strong cannabis. Thus, users of more potent cannabis are generally exposed to more delta‐9‐tetrahydrocannabinol. Smoking behaviour appears to be a stronger predictor for cannabis dependence severity than monthly delta‐9‐tetrahydrocannabinol dose.
- 1 December 2013
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 133 (2) , 776-780
Facilitators and barriers in treatment seeking for cannabis dependence
- 1 December 2013
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 133 (2) , 776-780
Facilitators and barriers in treatment seeking for cannabis dependence
- 1 December 2013
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 133 (2) , 352-359
Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study
- 1 December 2013
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 133 (2) , 352-359
Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study
Validation of self‐reported cannabis dose and potency: an ecological study
Aims: To assess the reliability and validity of self‐reported cannabis dose and potency measures.Design: Cross‐sectional study comparing self‐reports with objective measures of amount of cannabis and delta‐9‐tetrahydrocannabinol (THC) concentration.Setting: Ecological study with assessments at participants' homes or in a coffee shop.Participants: Young adult frequent cannabis users (n = 106) from the Dutch Cannabis Dependence (CanDep) study.Measurements: The objectively measured amount of cannabis per joint (dose in grams) was compared with self‐reported estimates using a prompt card and average number of joints made from 1 g of cannabis. In addition, objectively assessed THC concentration in the participant's cannabis was compared with self‐reported level of intoxication, subjective estimate of cannabis potency and price per gram of cannabis.Findings: Objective estimates of doses per joint (0.07–0.88 g/joint) and cannabis potency (1.1–24.7%) varied widely. Self‐reported measures of dose were imprecise, but at group level, average dose per joint was estimated accurately with the number of joints made from 1 g [limit of agreement (LOA) = −0.02 g, 95% confidence interval (CI) = −0.29; 0.26], whereas the prompt card resulted in serious underestimation (LOA = 0.14 g, 95% CI = −0.10; 0.37). THC concentration in cannabis was associated with subjective potency [‘average’ 3.77% (P = 0.002) and ‘(very) strong’ 5.13% more THC (P < 0.001) than ‘(very) mild’ cannabis] and with cannabis price (about 1% increase in THC concentration per euro spent on 1 g of cannabis, P < 0.001), but not with level of intoxication.Conclusions: Self‐report measures relating to cannabis use appear at best to be associated weakly with objective measures. Of the self‐report measures, number of joints per gram, cannabis price and subjective potency have at least some validity.
Validation of self‐reported cannabis dose and potency: an ecological study
Aims: To assess the reliability and validity of self‐reported cannabis dose and potency measures.Design: Cross‐sectional study comparing self‐reports with objective measures of amount of cannabis and delta‐9‐tetrahydrocannabinol (THC) concentration.Setting: Ecological study with assessments at participants' homes or in a coffee shop.Participants: Young adult frequent cannabis users (n = 106) from the Dutch Cannabis Dependence (CanDep) study.Measurements: The objectively measured amount of cannabis per joint (dose in grams) was compared with self‐reported estimates using a prompt card and average number of joints made from 1 g of cannabis. In addition, objectively assessed THC concentration in the participant's cannabis was compared with self‐reported level of intoxication, subjective estimate of cannabis potency and price per gram of cannabis.Findings: Objective estimates of doses per joint (0.07–0.88 g/joint) and cannabis potency (1.1–24.7%) varied widely. Self‐reported measures of dose were imprecise, but at group level, average dose per joint was estimated accurately with the number of joints made from 1 g [limit of agreement (LOA) = −0.02 g, 95% confidence interval (CI) = −0.29; 0.26], whereas the prompt card resulted in serious underestimation (LOA = 0.14 g, 95% CI = −0.10; 0.37). THC concentration in cannabis was associated with subjective potency [‘average’ 3.77% (P = 0.002) and ‘(very) strong’ 5.13% more THC (P < 0.001) than ‘(very) mild’ cannabis] and with cannabis price (about 1% increase in THC concentration per euro spent on 1 g of cannabis, P < 0.001), but not with level of intoxication.Conclusions: Self‐report measures relating to cannabis use appear at best to be associated weakly with objective measures. Of the self‐report measures, number of joints per gram, cannabis price and subjective potency have at least some validity.
- 14 May 2013
- Published by Wiley in International Journal of Methods in Psychiatric Research
- Vol. 22 (2) , 138-143
Reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in frequent cannabis users
The Severity of Dependence Scale (SDS) measures with five items the degree of psychological dependence on several illicit drugs, including cannabis. Its psychometric properties have not yet been examined in young adult frequent cannabis users, an eminently high‐risk group for cannabis dependence.Internal consistency and criterion validity of the SDS were investigated within an enriched community based sample of 577 Dutch frequent (≥ three days per week in the past 12 months) cannabis users between 18–30 years. Criterion validity was tested against the Composite International Diagnostic Interview (CIDI) 3.0 DSM‐IV diagnosis cannabis dependence, and psychometric properties were assessed separately for males and females and for ethnic subgroups.Principal component analysis showed that all items of the scale loaded on a single factor and reliability of the SDS total score was good (Cronbach's α = 0.70). However, criterion validity against the CIDI diagnosis cannabis dependence was low: area under curve (AUC) was 0.68 (95% confidence interval: 0.64–0.73) and at the optimal differentiating cut‐off (SDS ≥ 4), sensitivity was 61.3% and specificity 63.5%. Results were similar for subgroups on gender and ethnicity.While internal consistency of the SDS is good, its use as a screener to differentiate between dependence and non‐dependence within populations of young adult frequent cannabis users is not recommended. Copyright © 2013 John Wiley & Sons, Ltd.
- 14 May 2013
- Published by Wiley in International Journal of Methods in Psychiatric Research
- Vol. 22 (2) , 138-143
Reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in frequent cannabis users
The Severity of Dependence Scale (SDS) measures with five items the degree of psychological dependence on several illicit drugs, including cannabis. Its psychometric properties have not yet been examined in young adult frequent cannabis users, an eminently high‐risk group for cannabis dependence.Internal consistency and criterion validity of the SDS were investigated within an enriched community based sample of 577 Dutch frequent (≥ three days per week in the past 12 months) cannabis users between 18–30 years. Criterion validity was tested against the Composite International Diagnostic Interview (CIDI) 3.0 DSM‐IV diagnosis cannabis dependence, and psychometric properties were assessed separately for males and females and for ethnic subgroups.Principal component analysis showed that all items of the scale loaded on a single factor and reliability of the SDS total score was good (Cronbach's α = 0.70). However, criterion validity against the CIDI diagnosis cannabis dependence was low: area under curve (AUC) was 0.68 (95% confidence interval: 0.64–0.73) and at the optimal differentiating cut‐off (SDS ≥ 4), sensitivity was 61.3% and specificity 63.5%. Results were similar for subgroups on gender and ethnicity.While internal consistency of the SDS is good, its use as a screener to differentiate between dependence and non‐dependence within populations of young adult frequent cannabis users is not recommended. Copyright © 2013 John Wiley & Sons, Ltd.